Glenmark Pharmaceuticals Limited (GLENMARK) share price and analysis
GLENMARK last traded at ₹2,615.80 (-0.65%) on the NSE. Market cap ₹73,824 Cr (Mid cap), Pharma & Healthcare sector.
Overall rating: 4.6/10 (Average)
- Valuation: 3.6/10
- Profitability: 5.0/10
- Growth: 0.0/10
- Financial health: 5.5/10
- Price trend: 9.1/10
Long-term view: Neutral (watchlist). A mixed picture. Wait for better value or a clearer trend. Trade bias (next few weeks): Strong long. Trend and momentum are clearly pointing up.
Strengths of GLENMARK
- Long-term trend (+16.0% vs 200-DMA): Trading well above its 200-day average, a clear long-term uptrend.
- 50-DMA vs 200-DMA (+6.0% gap): 50-day average is above the 200-day (golden-cross setup), so medium-term momentum is up.
- Debt / equity (0.13): Comfortable debt level.
- Momentum (RSI 14) (RSI 67): Strong bullish momentum without being overbought.
- 6-month performance vs Nifty 50 (+12.5% vs +7.4%): Outperforming the Nifty 50.
- 52-week range (4% below high): Trading near its 52-week high, so buyers are in control.
- Current ratio (1.69): Comfortable liquidity.
Weaknesses of GLENMARK
- Revenue growth (YoY) (-29.8%): Sales are falling sharply.
- Profit growth (YoY) (-56.8%): Profits are falling sharply.
- Valuation (P/E) (P/E 50.9 vs sector 41.1): Trades at a 24% premium to sector peers.
- Free cash flow (Negative): Burning cash, because free cash flow is negative. Growth is being funded by debt, equity or reserves.
Key numbers
| Number | Value | Assessment | Normal range |
|---|---|---|---|
| P/E (TTM) | 50.9 | Expensive vs peers | 37.0–49.3 (sector median 41.1) |
| Forward P/E | 27.1 | Profits expected to grow | below today's P/E (50.9) and near 41 |
| Price / book | 6.58 | High | 2–6 |
| EPS (TTM) | ₹51.41 | Profitable | above ₹0 |
| Return on equity | 14.0% | Average | 15%+ (below 10% is weak) |
| Debt / equity | 0.13 | Low debt | below 1.0 (under 0.5 is great) |
| Net margin | 9.1% | Average | 10%+ (below 5% is thin) |
| Operating margin | 16.9% | Average | 20%+ strong, below 10% thin |
| Revenue growth | -29.8% | Shrinking | 10%+ a year (below 3% is weak) |
| Profit growth | -56.8% | Falling | 10%+ a year (falling is weak) |
| Dividend yield | 0.19% | Small payout | 1.5%+ (none is fine for growth firms) |
| Current ratio | 1.69 | Comfortable | 1.5+ (below 1 is tight) |
| 52W high | ₹2,714.00 | 4% below · near the high | price in the top 40% of its 52-week range |
| 52W low | ₹1,818.00 | Price is 44% above it | |
| 50-DMA | ₹2,389.47 | Price 9.5% above | price above it = short-term uptrend |
| 200-DMA | ₹2,254.89 | Price 16.0% above | price above it = long-term uptrend |
| 1Y return | +42.9% | Beat the Nifty 50 | Nifty 50 did −0.4% |
| Beta | 0.27 | Steadier than the market | 0.8–1.3 (1 = moves with market) |
| Promoter / insider | 49.0% | Moderate stake | 50%+ shows owner commitment |
| Institutions | 27.2% | Moderate interest | 30%+ is strong |
| Analyst target | ₹2,659.55 | 1.7% upside · 11 analysts | 8%+ upside |
Questions about GLENMARK
What is the share price of Glenmark Pharmaceuticals Limited (GLENMARK) today?
GLENMARK last traded at ₹2,615.80 (-0.65% on the day) on the NSE. Its 52-week range is ₹1,818.00 to ₹2,714.00. Prices are delayed and come from Yahoo Finance.
Is GLENMARK a good stock for the long term?
StockLens rates GLENMARK 4.6 out of 10 (Average) overall. Its long-term verdict is "Neutral (watchlist)": A mixed picture. Wait for better value or a clearer trend. Strengths: uptrend, bullish moving averages, low debt. Concerns: shrinking revenue, falling profits, expensive vs peers.
Is GLENMARK share overvalued?
GLENMARK trades at a P/E of 50.9 against a Pharma & Healthcare median of 41.1, which StockLens rates as "Expensive vs peers". Its price-to-book ratio is 6.58.
Is GLENMARK good for short-term trading?
The trade bias for the next few weeks is "Strong long": Trend and momentum are clearly pointing up. The price is 16.0% above its 200-day average and 14-day RSI is 67.
Which stocks are similar to GLENMARK?
Similar Pharma & Healthcare stocks of comparable size include Alkem Laboratories, Lupin, Biocon, Max Healthcare, Aurobindo Pharma. You can compare up to 4 of them side by side on StockLens.
About Glenmark Pharmaceuticals Limited
Glenmark Pharmaceuticals Limited, together with its subsidiaries, research, develops, manufactures, and sells generics, specialty medicines, and over the counter (OTC) pharmaceutical products in India, North America, Europe, and internationally. The company provides various products in the therapeutic areas of dermatology, respiratory, oncology, cardiology, diabetes, gynecology, gastroenterology, and anti-infective in the dosage forms of complex injectables and biologics, oral solids, liquids, topical products, and respiratory-metered dose inhaler, dry powder inhaler, and nasal sprays. Its product pipeline includes ISB 2001, a CD38 x BCMA x CD3 trispecific T cell engager, which is in Phase 1 clinical trial for indication of multiple myeloma; ISB 2301, a Multispecific Immune Cell Activator that is in preclinical trial for solid tumors; ISB 2302, a bispecific immune modulator with an indication for hematologic and solid tumors; and ISB 2501, a trispecific T-cell engager indicated for solid tumors. The company's pipeline also comprises ISB 880, an IL-1RAP antagonist monoclonal antibody, which is in Phase 2 clinical trial for the treatment of hidradenitis suppurativa; and telazorlimab and ISB 830-X8, a OX40 antagonist mAb for the treatment of atopic dermatitis. In addition, the company offers Ryaltris, fixed-dose nasal spray for the treatment of allergic rhinitis. The company was incorporated in 1977 and is based in Mumbai, India.
Stocks similar to GLENMARK
- Alkem Laboratories share price
- Lupin share price
- Biocon share price
- Max Healthcare share price
- Aurobindo Pharma share price
- Cipla share price
Compare GLENMARK with ALKEM, LUPIN, BIOCON
Educational information, not investment advice. Data from Yahoo Finance and NSE Indices; prices may be delayed.